글로벌 감마 아미노뷰티르산 트랜스아미나제 결핍증 치료 시장 - 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력 : 글로벌 감마 아미노부티르산 트랜스아미나제 결핍증 치료 시장

감마 아미노뷰티르산 트랜스아미나제 결핍증 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 위에 언급된 예측 기간 동안 시장이 3.90%의 CAGR로 성장할 것으로 분석합니다.

감마 아미노부티르산 트랜스아미나제 결핍증은 유아기에 발생하는 뇌 질환입니다. 감마 아미노부티르산(GABA) 대사의 드문 질환으로, 심각한 신생아-유아 간질성 뇌병증과 성장 가속이 특징입니다. 이 결핍증은 ABAT 유전자의 돌연변이로 인해 발생합니다. 이 유전자는 GABA-트랜스아미나제 효소를 만드는 지침을 제공합니다. 감마 아미노부티르산 트랜스아미나제 결핍증의 증상은 정신운동성 방사, 과잉 반응, 발작 , 근긴장 저하, 무기력증 및 EEG 이상입니다.

감마 아미노부티르산 트랜스아미나제 결핍증 유병률 증가, 의료비 지출 증가, 첨단 치료에 대한 수요 급증, 정부 자금 지원 증가, 희귀 질병에 대한 인식을 확산하기 위한 정부 및 민간 기관의 이니셔티브 증가는 감마 아미노부티르산 트랜스아미나제 결핍증 치료 시장을 확대할 요인입니다.

연구 개발 활동의 증가와 조기 진단 기술 개발의 확대는 2021~2028년 예측 기간 동안 감마 아미노부티르산 트랜스아미나제 결핍증 치료 시장에 유익한 기회를 제공할 것입니다.

그러나 플루마제닐과 관련된 메스꺼움, 구토, 현기증, 맥박 증가, 두통 , 시야 흐림 등 부작용과 치료 비용이 높아 시장 성장을 방해하는 요인이 되고 있으며, 위에서 언급한 예측 기간 동안 감마 아미노뷰티르산 트랜스아미나제 결핍증 치료 시장에 더욱 큰 어려움을 초래할 것입니다.

This gamma aminobutyric acid transaminase deficiency treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the gamma aminobutyric acid transaminase deficiency treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market Scope and Market Size

The gamma aminobutyric acid transaminase deficiency treatment market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of treatment, the gamma aminobutyric acid transaminase deficiency treatment market is segmented into flumazenil and others.
• On the basis of diagnosis, the gamma aminobutyric acid transaminase deficiency treatment market is segmented into physical exam, laboratory tests, genetic testing and others.
• On the basis of dosage, the gamma aminobutyric acid transaminase deficiency treatment market is segmented into solution, injection and others.
• On the basis of route of administration, the gamma aminobutyric acid transaminase deficiency treatment market is segmented into intravenous and others.
• On the basis of end-users, the gamma aminobutyric acid transaminase deficiency treatment market is segmented into clinic, hospital and others.

The gamma aminobutyric acid transaminase deficiency treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market Country Level Analysis

Gamma aminobutyric acid transaminase deficiency treatment market is analyzed and market size information is provided by the country, treatment, diagnosis, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the gamma aminobutyric acid transaminase deficiency treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the gamma aminobutyric acid transaminase deficiency treatment market due to the presence of major key players, high disposable income, high healthcare expenditure and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Gamma aminobutyric acid transaminase deficiency treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market Share Analysis

Gamma aminobutyric acid transaminase deficiency treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to gamma aminobutyric acid transaminase deficiency treatment market research.

감마 아미노뷰티르산 트랜스아미나제 결핍증 치료 시장 보고서에 포함된 주요 기업으로는 Fresenius Kabi AG, Pfizer Inc., ScinoPharm Taiwan, Midas Pharma GmbH., Hunan Warrant Chiral Pharmaceutical Co., Fuan Pharmaceutical (Group) Co.,Ltd., Hubei Haosun Pharmaceutical Co.,Ltd., Jiangsu Nhwa Pharmaceutical Co.,Ltd., Baxter, Zhejiang Xianju Pharmaceutical Co.,Ltd., Centurion Healthcare Private Limited 등이 있으며, 국내 및 글로벌 기업도 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA) 및 남미에 대해 별도로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.

SKU-66486